AMPYRA

LOE Approaching

dalfampridine

NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Jan 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2

Mechanism of Action

Potassium Channel Antagonists

Pharmacologic Class:

Potassium Channel Blocker

Clinical Trials (2)

NCT01656148Phase 4Completed

FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra

Started Jun 2012
108 enrolled
Multiple Sclerosis
NCT01480063N/ACompleted

An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice

Started Apr 2012
4,734 enrolled
Multiple Sclerosis